×
Close
Access complete features of Elixir
Elixir
Drug Screener
Login
×
Close
Searching Query
Please wait while we search for your query
Your search results are ready!
View Results
×
Close
Loading Screen
Please wait while we are loading your screen
Your screen is ready!
View Screen
×
Close
Examiner Insights
USPTO PAIR Documents
File History
PTAB Proceedings
Orange Book
Assignee Citation
Dossier Documents
Events History
Events History
SPC Events
Unitary Documents
Patent Citation
Country-wise Revenue Breakdown
Loading Examiner's Profile.
Loading USPTO PAIR Documents.
Loading PTAB Proceedings.
Loading Orange Book.
Loading Assignee Chart...
Loading Legal Events...
Loading SPC Events...
Loading Unitary Documents...
Loading File History...
Loading File History...
Loading File History...
Last updated on - 11 Mar, 2025
Generic
: Naloxegol
Revenue
: $0.45 Billion
Source
:
Verified Market Reports
Year
: 2022
Country
Generic/Branded
Drug Name
Revenue
Source
Year
US
Branded
Movantik (U.S) / Moventig (Europe)
$200 Million
Grunenthal Press Release
2023
CA
Branded
Movantik
$0.372 Million
Knight Therapeutics Announcement
2016
EP
Branded
Moventig
$70 Million
European Pharmaceutical Review
2016
Discover Your Next Blockbuster Drug
×
Close
Apply Filter
Patent Category
Country
Legal Status
Popular screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View list
NCE-1 Patent Expiry after 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach exclusivity expiry
View list
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View list
EMA Approved Drugs
Create your own screen
Last updated: March 12th, 2025
Apply Filters
Export List
Actions
Patent Number
Company
Product
Brand
Legal Status
Grant Date
Revenue
Patent Expiry Date
Get updates in your inbox
Your Work Email:
*
* Please enter a valid email address
Message for us (Optional):